Nurse Volunteers on the Front Lines of the Vaccination Effort

Joanne Disch, PhD, RN, FAAN, is professor ad honorem at the University of Minnesota School of Nursing, Minneapolis, and Ellen Elpern, MSN, RN, is a retired advanced practice nurse, formerly at Rush University Medical Center, Chicago.

Nurse volunteers as an essential resource.

As of April 15, 2021, there have been over 31 million cases of COVID-19 in the United States and over 561,000 deaths. Sobering numbers. But there are some heartening numbers as well: 198 million vaccination shots have been administered so far, with 3 million doses now being given per day. To reach and continue to meet the current pace has required an extraordinary ramp-up of sites—and of the number of individuals administering the vaccines. An essential resource that’s emerged is the use of nurses as volunteers to help staff these sites.

For more than a year, the public has witnessed the compassion, competence, and heroism of nurses who are on the front lines of the COVID pandemic. Those of us who are nurses and not in the clinical setting watched with pride and empathy, knowing better than most what these nurses were experiencing—and wishing there were something that we could do. Stepping forward to volunteer for service in a vaccine clinic is one way to make a difference. These volunteer opportunities are as varied as the vaccination sites themselves, but in all cases the effort is being enriched by the active engagement of nurses, retired and otherwise.

Defuniak Springs, Florida

2021-04-16T09:15:42-04:00April 16th, 2021|COVID-19, infectious diseases, Nursing, nursing career|0 Comments
Read More

Remembering the Polio Vaccine Rollout, Addressing Concerns Today

‘A Most Welcome Spring.’

That’s the title of the editorial in the recently published April issue of AJN. And if you receive the print issue or go to our Web site, www.ajnonline.com, I think you’ll see that our cover reflects an image that harkens to the end of a hard pandemic winter of isolation and—for many families—desolation. Spring has arrived, along with a feeling of hope that the vaccines will allow the world to open again, IF we can do so with caution and are successful in vaccine campaigns.

Remembering the relief at having a polio vaccine.

I was in kindergarten when Jonas Salk’s polio vaccine was rolled out. I remember my mother telling me that everyone was going to be getting a new medicine and I vividly recall my entire class lining up to get the injection from the school nurse.

I remember my mother being very happy about it because a boy in the neighborhood—a friend of my brother—had had polio and now wore leg braces and used crutches. When she saw him, she would sometimes say, “too bad the vaccine came too late for John.”

Nurses’ role in addressing vaccine concerns.

2021-04-26T11:50:12-04:00April 5th, 2021|COVID-19, infectious diseases, Nursing, patient engagement, Public health|0 Comments
Read More

‘Right Under Our Noses’: Nightmarish Nursing Home Conditions During the Pandemic

As vaccinations increase and COVID-19 infection rates in nursing homes plummet, it’s easy to forget just how bad things got in many of them and how ill-equipped many were in the the early months of the pandemic to provide humane and effective care.

The following excerpt is from our March Reflections essay, “Right Under Our Noses: Nursing Homes and COVID-19,” which was written by a California nursing professor who volunteered to join a California Medical Assistance Team. The mission of her team was to bring aid to a skilled nursing facility where the coronavirus was rapidly infecting both patients and staff, a facility with little PPE available and many staff members refusing to come to work out of fear of infection.

The conditions I saw were shocking, even to an experienced nurse. I saw soggy diapers on the floor at the heads of many beds on most mornings. One day a bedbound patient needed the bedpan. I searched every closet and drawer but there were no supplies. I filled a basin with warm water and cut up a PPE gown to make washcloths to clean the patient. On the second day of my deployment I realized that many of the […]

2021-03-18T12:10:25-04:00March 18th, 2021|COVID-19, Ethics, infectious diseases, Nursing, nursing perspective, safe staffing|1 Comment
Read More

Johnson and Johnson Vaccine a Valuable Addition to the COVID-19 Toolbox

With the emergency use authorization (EUA) of the Janssen Pharmaceuticals/Johnson & Johnson COVID-19 vaccine, three vaccines are now available in the U.S. to prevent SARS-CoV-2 hospitalizations and death. The newest vaccine, given as a single dose and stable at refrigeration temperatures for at least three months, presents far fewer logistical challenges in getting doses to consumers.

All of the three current U.S. vaccines use a single protein from SARS-CoV-2 to enable the body to react to the whole virus. The Pfizer/BioNTech and Moderna vaccines are messenger RNA vaccines that use a synthetic version of part of the SARS-CoV-2 genome to teach our cells to replicate the spike protein found on the surface of the virus. This copy of the protein then stimulates the immune system to produce antibodies and other cells that will recognize the actual virus if it is encountered in the future.

The new vaccine employs a different mechanism to produce the same result. A human adenovirus, modified to disable its ability to multiply and infect, acts as a “vector” to carry a gene from the spike protein into our own cells, where the protein is replicated and activates the immune system as above.

(The Oxford/AstraZeneca COVID-19 vaccine, currently in use in the UK, Canada, and Australia, is also a vector vaccine. Granted emergency use listing by the World Health […]

2021-03-08T12:31:39-05:00March 8th, 2021|COVID-19, infection control, infectious diseases, Nursing, Public health|0 Comments
Read More

COVID-19 Vaccines Explained

As we in the U.S. struggle to set up systems for the rapid administration of SARS-CoV-2 vaccinations, what do nurses need to know about these vaccines?

Two vaccines have received emergency use authorization (EUA) in the U.S.—one manufactured by Pfizer/BioNTech, the other by Moderna. (A third, manufactured by AstraZeneca, is likely to receive EUA by April.) New, more efficient vaccine technologies along with a huge financial investment by the U.S. government have produced these products in a much shorter time frame than has been typical for other vaccines.

Currently available vaccines.

The two vaccines that are available now are messenger RNA, or mRNA, vaccines. This type of vaccine has been developed and studied for decades for possible use in preventing influenza, Zika, and other infectious diseases. Human mRNA is a strand of genetic material used for cell building and maintenance. For SARS-CoV-2 vaccines, mRNA based on part of the SARS-CoV-2 genome is synthesized and standardized in a lab.

When administered in a vaccine, this mRNA delivers to our cells the instructions  to replicate a “spike protein” found on the surface of the SARS-CoV-2 virus. (Important to know and tell patients: The mRNA never enters the nuclei of our cells, and can’t be incorporated into our own DNA.) After a cell follows these instructions and “posts” the spike protein replica on its surface, the immune system recognizes it as foreign […]

2021-01-19T11:08:24-05:00January 19th, 2021|infectious diseases, Nursing, Public health|0 Comments
Read More

Comment ground rules

1. Please be respectful.
2. We moderate all comments.

Content disclaimer

Views expressed on the blog are solely those of the authors or persons quoted. They do not necessarily reflect AJN’s views or those of Wolters Kluwer Health/Lippincott Williams and Wilkins.
Go to Top